Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

Fig. 3

Changes in Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) (a), CD19 + B cells (b) and CD4+ T cells (c) over seven cycles of rituximab (RTX). For each cycle, values are presented at three time points, i.e. before the first infusion, before the second infusions two weeks apart and at 3 or 6 months post treatment. Results are shown as the median and interquartile range in patients with available data. The level defining low disease activity is represented (DAS28 ≤ 3.2). The limits of the reference range are represented for CD19+ B cells (between 200 and 400/mm3) and for CD4+ T cells (between 700 and 1100/mm3)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us